Moderna, Inc.
Clinical trials sponsored by Moderna, Inc., explained in plain language.
A biotechnology company known for its mRNA-based vaccines and therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial Results expected Sep 2026 (estimated)
- No treatment, just data: new study tracks rare metabolic disease Results expected Sep 2026 (estimated)
- Could this mRNA vaccine stop the virus behind mono and certain cancers? Results expected Oct 2026 (estimated)
- Moderna launches first human test of mRNA vaccine against Epstein-Barr virus Results expected Oct 2026 (estimated)
- New mRNA therapy aims to control blood sugar in rare genetic disease Results expected Nov 2026 (estimated)
-
Can mRNA technology outsmart shingles? a new vaccine trial aims to find out
Vaccine Stopped earlyThis trial tests an experimental mRNA vaccine, mRNA-1468, to see if it can safely prevent shingles in healthy adults aged 50 and older. Participants receive either the new vaccine, a placebo, or an existing shingles vaccine (Shingrix) to compare safety and immune response. The st…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 07, 2026 00:00 UTC
-
New mRNA vaccine aimed at preventing common but risky virus
Vaccine Stopped earlyThis phase 3 trial tested an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in healthy people aged 16 to 40. The study enrolled over 7,400 participants, focusing on women who had never been infected with CMV. The vaccine aims to trigger an immune response to …
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:04 UTC
-
COVID vaccine trial for babies halted early – Here's what we know
Vaccine Stopped earlyThis study looked at whether the mRNA-1273.214 COVID-19 vaccine is safe and works in infants as young as 12 weeks to under 6 months old. It was a small, early-stage trial that was stopped before completion. The main goal was to check for side effects like fever, fussiness, and in…
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:00 UTC
-
MRNA therapy trial for rare acidemia halted early
Disease control Stopped earlyThis study tested an mRNA therapy called mRNA-3705 in 18 people with a rare genetic condition called methylmalonic acidemia, which causes harmful acid buildup. The therapy aimed to help the body produce a missing enzyme to lower acid levels. The trial was terminated early, so fin…
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC